Research programme: sphingolipid modulator analogues - QUE OncologyAlternative Names: Q 102
Latest Information Update: 07 Jun 2016
At a glance
- Originator QUE Oncology
- Mechanism of Action Sphingolipid modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 07 Jun 2016 Preclinical trials in Prostate cancer in USA (PO) before June 2016